MaxCyte, Inc. (MXCT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 9.89M USD | Liabilities, Current |
| Cash and equivalents | 15.04M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 3.92M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 7.80M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $9.89M | $15.04M | (m) | $3.92M | $7.80M | (m) |
| 2026-03-31 | (m) | $10.21M | $14.56M | (m) | $4.25M | $7.63M | (m) |
| 2025-12-31 | (m) | $14.27M | $20.07M | (m) | $3.50M | $7.55M | (m) |
| 2025-09-30 | (m) | $16.10M | $12.97M | (m) | $8.31M | $7.61M | (m) |
| 2025-06-30 | (m) | $11.55M | $15.22M | (m) | $5.75M | $7.93M | (m) |
| 2025-03-31 | (m) | $12.73M | $23.39M | (m) | $5.53M | $8.27M | (m) |
| 2024-12-31 | (m) | $15.78M | $27.88M | (m) | $4.68M | $8.91M | (m) |
| 2024-09-30 | (m) | $17.62M | $36.96M | (m) | $4.56M | $10.39M | (m) |
| 2024-06-30 | (m) | $12.28M | $37.51M | (m) | $4.58M | $11.16M | (m) |
| 2024-03-31 | (m) | $13.48M | $22.25M | (m) | $5.99M | $11.96M | (m) |
| 2023-12-31 | (m) | $17.86M | $46.51M | (m) | $5.78M | $12.23M | (m) |
| 2023-09-30 | (m) | $16.65M | $49.17M | (m) | $8.17M | $12.53M | (m) |
| 2023-06-30 | (m) | $13.20M | $54.56M | (m) | $7.61M | $11.02M | (m) |
| 2023-03-31 | (m) | $16.64M | $37.83M | (m) | $8.29M | $10.26M | (m) |
| 2022-12-31 | (m) | $15.43M | $11.06M | (m) | $11.65M | $8.58M | (m) |
| 2022-09-30 | (m) | $16.76M | $43.02M | (m) | $7.43M | $7.91M | (m) |
| 2022-06-30 | (m) | $18.11M | $109.17M | (m) | $7.43M | $7.72M | (m) |
| 2022-03-31 | (m) | $15.55M | $239.78M | (m) | $8.63M | $6.58M | (m) |
| 2021-12-31 | (m) | $15.62M | $47.78M | (m) | $6.88M | $5.20M | (m) |
| 2021-09-30 | (m) | $12.58M | $58.97M | (m) | $5.96M | $4.15M | (m) |
| 2021-06-30 | (m) | $12.53M | $37.42M | (m) | $5.72M | $4.17M | (m) |
| 2020-12-31 | (m) | $11.61M | $18.76M | (m) | $5.17M | $4.32M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |